Purple Biotech Ltd.
PPBT
Rank in Stocks
#34107
Purple Biotech Ltd., a clinical-stage company, is focused on creating therapies... Purple Biotech Ltd., a clinical-stage company, is focused on creating therapies for cancer patients in the United States, specifically addressing challenges like tumor immune evasion and drug resistance. Its diverse oncology pipeline includes CM24, a humanized monoclonal antibody that targets and blocks carcinoembryonic antigen related cell adhesion molecule 1 (CEACAM1). Currently in Phase 2 clinical trials, CM24 is being investigated as a combination therapy with anti-PD-1 checkpoint inhibitors for treating pancreatic ductal adenocarcinoma. Another candidate is NT219, a small molecule compound in Phase 1/2 clinical trials, which functions by inhibiting insulin receptor substrate 1 and 2 (IRS1/2) and signal transducer and activator of transcription (STAT). This compound is being developed for recurrent and/or metastatic squamous cell carcinoma of the head and neck, or colorectal adenocarcinoma. Furthermore, IM1240, a multi-valent antibody designed to activate an anti-tumoral immune response against 5T4-positive tumors, is in its preclinical stage. The company has established significant collaborations, including an agreement with Bristol Myers Squibb Company for Phase 2 clinical trials to assess CM24 in combination with the PD-1 inhibitor nivolumab and chemotherapy, as well as a partnership with Mor Research Applications. Formerly known as Kitov Pharma Ltd., the company adopted the name Purple Biotech Ltd. in December 2020 and is headquartered in Rehovot, Israel.
Share Price
$1.34
Last synced: 2026-11-09
Market Cap
$68.87K
Change (1 day)
2.29%
Change (1 year)
-83.86%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Purple Biotech Ltd. (PPBT)
Category
Healthcare
Operating Margin for Purple Biotech Ltd. (PPBT)
Operating Margin as of November 2026 TTM: 0.00%
According to Purple Biotech Ltd.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Purple Biotech Ltd. from 2013 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | -100.00% |
| 2023 | -11,374.13% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | -100.00% |
| 2020 | -1,323.90% | 85.01% |
| 2019 | -715.60% | -8.56% |
| 2018 | -782.60% | -93.46% |
| 2017 | -11,966.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Purple Biotech Ltd.'s operating margin
What was Purple Biotech Ltd.'s operating margin in 2025?
In 2025, Purple Biotech Ltd.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Purple Biotech Ltd.'s operating margin changed since 2020?
From 2020 to 2025, Purple Biotech Ltd.'s operating margin was highest in 2025 (0.00%) and lowest in 2023 (-11,374.13%).
How does Purple Biotech Ltd.'s operating margin compare with similar companies?
Purple Biotech Ltd.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.